ReviewSubstance abuse and rehabilitation2015
New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.
Review in Substance abuse and rehabilitation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders.The Cochrane database of systematic reviews · 2020Pooled it
- A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence.Addiction science & clinical practice · 2017Pooled it
- Barriers to progressing through a methadone maintenance treatment programme: perspectives of the clients in the Mid-West of Ireland's drug and alcohol services.BMC health services research · 2018Trial
- Trial
- Risk of opioid overdose during buprenorphine treatment for opioid use disorder in the fentanyl era.Addictive behaviors · 2026Article
- Republication of "How Will the Foot and Ankle Orthopedic Community Respond to the Growing Opioid Epidemic?"Foot & ankle orthopaedics · 2023Review
- Review
- Evaluation of Injectable Naloxone-Releasing Hydrogels.ACS applied bio materials · 2020Article
- Opioid maintenance treatment of pregnant women in the Scandinavian countries.Nordisk alkohol- & narkotikatidskrift : NAT · 2020Article
- Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support.Journal of substance abuse treatment · 2019Article
- Review
- Buprenorphine/Naloxone (ZubsolvCNS drugs · 2018Review
- Pharmacogenetics of Opioid Use Disorder Treatment.CNS drugs · 2018Review
- Suboxone: Rationale, Science, Misconceptions.Ochsner journal · 2018Article
- Indications for Opioid Antagonists.Current pain and headache reports · 2017Review
- Pain Management of Patients with Substance Abuse in the Ambulatory Setting.Current pain and headache reports · 2017Review
- Article
- Synthesis and opioid receptor binding of indium (III) and [Tetrahedron · 2016Article
- Relapse during opioid use disorder treatment: A pilot study to understand the reasons for opioid use during treatment.Industrial psychiatry journalArticle
- Opioid Use Disorder and Pregnancy.Missouri medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opioid maintenance therapy is a well-established first-line treatment approach in opioid dependence. Buprenorphine, a partial opioid agonist, has been found by numerous studies to be an effective and safe medication in the treatment of opioid dependence. At present, buprenorphine is available as a monodrug or in a fixed 4:1 ratio combination with naloxone. A diminished risk of diversion and abuse for the buprenorphine-naloxone combination is likely but not firmly established. Conventional formulations are given sublingually to avoid the hepatic first-pass effect. A novel film tablet is available only in the US and Australia. Other novel, sustained-release formulations (implant, depot) are currently being developed and tested. Recent studies, including a Cochrane meta-analysis, suggest that the retention with buprenorphine is lower than for methadone, but that buprenorphine may be associated with less drug use. Higher doses of buprenorphine are associated with better retention rates. Buprenorphine has a ceiling effect at the opioid receptor with regard to respiratory depression, and may cause fewer fatal intoxications than methadone. Possible antidepressant effects of buprenorphine and its use in comorbid psychiatric patients has not been studied in much detail. Clinical implications are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.